Biometrix Technology Co, Ltd

CEO : KIM TAE SEON

Biometrix Technology. Inc. has developed the world’s first 9G technology that arranges 9 guanine bases at regular intervals in a molecular recognition format and DAGON technology that can detect marker proteins up to a pg/ml level. Based on this core technology, we have established a platform technology applicable to the detection of various genes and proteins, and based on this, we sell IVD diagnostic devices and reagents. Using this technology, Biometrix Technology has entered into the market for cardiovascular disease prevention and management by using cardiovascular monitoring products to easily manage cardiovascular diseases. In addition, we are working hard to lead the field of early cancer screening molecular diagnostics that no one has entered the market yet. Biometrix Technology continues to showcase the world’s leading cardiovascular and early-stage cancer molecular diagnostic reagents and hopes to become the world’s leading professional healthcare company.